Sign In
Buy RVVTF
$0.0190
+0.0010 (+5.56%)
At Close: Jul 31, 2026
Revive Therapeutics announces published results on Bucillamine as potential inhibitor of SARS-CoV-2 infection Delta variant
09:03am, Tuesday, 16'th Nov 2021
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced a research study showing the potent thiol drugs, like Bucillamine, inhibit SARS-CoV-2 infection in vitro — specifically the Delta variant.
Revive Therapeutics announces published results on Bucillamine as potential inhibitor of SARS-CoV-2 infection Delta variant
08:48am, Tuesday, 16'th Nov 2021
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced a research study showing that potent thiol drugs, such as Bucillamine, inhibit SARS-CoV-2 infection in vitro — especially the Delta varia
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant
06:00am, Tuesday, 16'th Nov 2021
TORONTO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the res
Revive Therapeutics enters into research collaboration agreement for development of psilocybin microneedle patch
08:50am, Wednesday, 03'rd Nov 2021
Revive Therapeutics Ltd said it has entered into a research collaboration agreement with PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, to evaluate the delivery of psilocybin
Revive Therapeutics says DSMB supports continuation of its Phase 3 trial of Bucilllamine for mild COVID-19
09:35am, Tuesday, 26'th Oct 2021
Revive Therapeutics Ltd announced that the Independent Data and Safety Monitoring Board (DSMB) continues to support its Phase 3 clinical trials to evaluate the efficacy and safety of Bucilllamine in p
Revive Therapeutics added to AdvisorShares Psychedelics ETF
10:54am, Tuesday, 21'st Sep 2021
Revive Therapeutics Ltd. reports that AdvisorShares Investments LLC, a leading sponsor of actively managed exchange-traded funds (ETFs), has included the company in the inaugural launch of its Advisor
Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF
09:45am, Tuesday, 21'st Sep 2021
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the re
Revive Therapeutics expands clinical stage pipeline with Ganoderma lucidum license deal
07:34am, Wednesday, 18'th Aug 2021
Revive Therapeutics Ltd told investors it has boosted its clinical-stage product pipeline by striking an exclusive license deal to advance medicinal mushroom Ganoderma lucidum compounds to treat canc
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer
05:46pm, Tuesday, 17'th Aug 2021
TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the rese
Revive Confirms No Material Undisclosed Information
08:12am, Thursday, 12'th Aug 2021
TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (Frankfurt:31R), a specialty life sciences company focused on the rese
Revive Therapeutics advancing psilocybin to FDA clinical studies for methamphetamine use disorder and stroke
10:03am, Tuesday, 10'th Aug 2021
Revive Therapeutics Ltd said it is advancing to Food and Drug Administration (FDA) clinical studies with psilocybin for methamphetamine use disorder and stroke. In a statement, Revive CEO Michael Fr
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline
07:48am, Tuesday, 10'th Aug 2021
TORONTO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the rese
Revive Therapeutics advancing repurposed gout drug to fight coronavirus and pushing into psychedelic medicine
01:46pm, Tuesday, 20'th Jul 2021
Specialty life sciences company focused on developing drugs for rare disorders and infectious diseases Advancing clinical development of gout drug Bucillamine for infectious diseases, including COVID-
Leede Jones Gable looking forward to final data from Revive Therapeutics Ltd's Phase 3 Bucillamine coronavirus trial
12:09pm, Friday, 16'th Jul 2021
Leede Jones Gable, the investment firm, says that the scientific rationale behind Revive Therapeutics Ltd's (CSE:RVV) (OTCMKTS:RVVTF) (FRA:31R) rheumatoid arthritis drug Bucillamine being a potential
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
01:31pm, Thursday, 15'th Jul 2021
TORONTO, July 15, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the res
